ResearcherAffiliated Hospital of Nantong UniversityNo recent work listed

Jing Qian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2198-7441; OpenAlex author ID A5071924811. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2020: 2 papers

Papers 2

Analysis of lncRNA-mRNA networks after MEK1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcp.29255 ↗
MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. Co-author DOI 10.1016/j.lfs.2020.118148 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yu Shi · 2 shared papers, 2020 · strength 0.23
- Paper MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. DOI 10.1016/j.lfs.2020.118148 ↗
- Paper Analysis of lncRNA-mRNA networks after MEK1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma. DOI 10.1002/jcp.29255 ↗
Jianbo Ma · 1 shared paper, 2020 · strength 0.13
- Paper MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. DOI 10.1016/j.lfs.2020.118148 ↗
Yong Kwon Han · 1 shared paper, 2020 · strength 0.13
- Paper MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. DOI 10.1016/j.lfs.2020.118148 ↗
Yan Wang · 1 shared paper, 2020 · strength 0.13
- Paper MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. DOI 10.1016/j.lfs.2020.118148 ↗
Ninghua Yao · 1 shared paper, 2020 · strength 0.10
- Paper Analysis of lncRNA-mRNA networks after MEK1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma. DOI 10.1002/jcp.29255 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.